Summary:
In patients with diabetic macular edema (DME), intravitreal dexamethasone implant treatment (DEX) significantly shortened the time to DME resolution compared to sham treatment, though it was associated with an increased risk of elevated intraocular pressure.
| PICO | Description |
|---|---|
| Population | Patients with diabetic macular edema (DME), as analyzed in a post hoc review of the MEAD study. |
| Intervention | Intravitreal dexamethasone implant treatment (DEX). |
| Comparison | Sham treatment. |
| Outcome | DEX significantly shortened time to resolution of DME when compared to sham. However, higher central retinal thickness (CRT) was associated with longer resolution times. DEX treatment was also linked to an increased risk of elevated intraocular pressure. |
Source: Carolina C S Valentim, et al. “Baseline factors affecting diabetic macular oedema resolution after intravitreal dexamethasone implant treatment: post hoc analysis of the MEAD study.” Read article here.
